LM N°1/ 2024. MOTIVATION TO STUDY THE EFFECT OF PLATELET-RICH PLASMA (PRP) ON POST-CHEMOTHERAPY ALOPECIA (APC) AND POST-ENDOCRINE THERAPY ALOPECIA (APE). Leore LAVIN MS, Alex PAN MD, Anthony ROSSI MD, Antoine TURZI.
LM N°1/ 2024. CORRECTION OF AGE-RELATED CHANGES WITH AUTOLOGOUS THROMBIN-ACTIVATED PRP AND HYALURONIC ACID IN COMBINATION WITH RF-MICRONEEDLING EQUIPMENT. Inna SHARYPOVA, MD, PhD. Andrey ALENICHEV, MD, PhD.
LM N°1/ 2024. PLATELET-RICH PLASMA AS A SAFE AND EFFECTIVE AUTOLOGOUS TREATMENT FOR CHRONIC WOUND HEALING. Solange VISCHER, Antoine TURZI.
LM N°1/ 2024. OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES. Andreas PIGNI. Legal Affairs, RegenLab SA.
LM N°1/ 2024. REGENPRP®, A STANDARDIZED AUTOLOGOUS PLATELET CONCENTRATE. 10 YEARS OF RESEARCH AND PRACTICE. Pr Barbara Hersant Editor-in-Chief, L&M
No More Posts